AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis - LARVOL DELTA

Adebrelimab Plus Ivarmacitinib With or Without Chemotherapy as First-Line Treatment for Advanced NSCLC: A Phase 2 Trial (IASLC-WCLC 2026) - P2, P4 | "First-line pembrolizumab plus itacitinib (NCT03425006) resulted in a 12-week objective response rate (ORR) of 62% and a median progression-free survival (PFS) of 15.6 months in 23 patients with metastatic NSCLC and PD-L1 tumor proportion score (TPS) ≥50%...Cohort B will additionally receive platinum-based doublet chemotherapy for 2 cycles (if pemetrexed is used for non-squamous NSCLC, it will be continued until disease progression or intolerable toxicity) since the initiation of adebrelimab treatment...The 95% confidence intervals (CIs) of ORR and DCR will be calculated using the Clopper-Pearson method. Median survival will be estimated using the Kaplan-Meier method, and the corresponding 95% CIs will be calculated using the Brookmeyer-Crowley method."

Clinical • IO biomarker • Metastases • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • ALK • CD8 • EGFR • MET • ROS1

Emerging and Investigational JAK Inhibitors for Rheumatoid Arthritis: Efficacy and Safety. (PubMed, Drug Des Devel Ther) - "Peficitinib has the most mature evidence base, including Phase 3 efficacy, radiographic protection, long-term extension data, and pooled safety analyses. Ivarmacitinib has phase 3 and exploratory MRI data, whereas the phase 3 trial of TLL-018 has reached primary completion, with sponsor-reported topline findings available but complete results not yet published. CPL409116/CPL'116 remains supported by limited Phase 2 evidence. Decernotinib represents an informative historical proof-of-concept programme. Overall, no emerging agent has yet demonstrated a reproducible advantage over established JAK inhibitors in sustained remission, structural preservation, difficult-to-treat disease, or overall benefit-risk balance. Future development should prioritise active comparators, prespecified structural outcomes, prolonged safety assessment, and prospectively validated treatment-specific biomarkers."

Journal • Review • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Efficacy and Health-Related Quality of Life Improvements with Ivarmacitinib in Biological DMARD-Experienced Rheumatoid Arthritis Patients: A Post-Hoc Analysis from a Phase III Trial (ACR Convergence 2026) - No abstract available

Clinical • HEOR • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - P2/3 | N=294 | Not yet recruiting | Sponsor: Chinese SLE Treatment And Research Group

Head-to-Head • New P2/3 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial. (PubMed, J Eur Acad Dermatol Venereol) - P3 | "Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo-controlled period. Because the extension phase had no placebo control after Week 16, long-term efficacy findings should be interpreted as descriptive."

Journal • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series. (PubMed, Clin Cosmet Investig Dermatol) - "This retrospective case series describes eight male patients with Hurley stage III HS who received tofacitinib (n=3), upadacitinib (n=4), or ivarmacitinib (n=1) after inadequate response to conventional therapies. However, responses and follow-up durations were heterogeneous, and the small sample size precludes comparisons between agents. Prospective controlled studies with standardized assessment timepoints and longer follow-up are needed to clarify efficacy, durability, and long-term safety."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • Pain

Predictors of ASAS40 Response to Ivarmacitinib in Patients with Active Ankylosing Spondylitis: A Post-hoc Analysis of a Randomized, Double-blind, Placebo-controlled Phase II/III Trial (ACR Convergence 2026) - No abstract available

Clinical • P2/3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy of Ivarmacitinib for Mild-to-Severe Alopecia Areata: A Case Series (EADV 2026) - No abstract available

Clinical • Alopecia • Immunology

Efficacy and Safety of Ivarmacitinib in Adult and Pediatric Patients with Alopecia Areata: A Real-World Analysis (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology • Pediatrics

Real‑World Efficacy of Ivarmacitinib for Eyebrow and Eyelash Alopecia in Patients with Alopecia Areata (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Alopecia • Immunology

A Case Report: A 14-Year-Old Patient with Severe Alopecia Areata, Vitiligo, and Atopic Dermatitis Undergoing Ivarmacitinib Treatment (EADV 2026) - No abstract available

Case report • Clinical • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Vitiligo

Concomitant Improvement of Severe Alopecia Areata and Vitiligo with the Selective JAK1 Inhibitor Ivarmacitinib: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Alopecia • Dermatology • Immunology • Vitiligo

Efficacy and Safety of Ivarmacitinib in the Treatment of Severe Alopecia Areata: A Retrospective Study (EADV 2026) - No abstract available

Retrospective data • Alopecia • Immunology

Ivarmacitinib Response Trajectories in Severe Alopecia Areata: A Post Hoc Analysis of Early, Gradual, Late, and Non‑Responder Subgroups Over 52 Weeks (EADV 2026) - No abstract available

Retrospective data • Alopecia • Immunology

Rapid Efficacy of Ivarmacitinib in Promoting Scalp Hair, Eyebrow, and Eyelash Regrowth in Alopecia Areata: Chinese Single-Center Real-World Experience in Adults and Minors (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Alopecia • Immunology

Efficacy of Ivarmacitinib in Severe Alopecia Areata by Prior Treatment History: A Post-Hoc Analysis of a Phase 3 Trial (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Alopecia • Immunology

Efficacy of Ivarmacitinib in Adults with Severe Alopecia Areata Across Baseline Characteristics: A Post-hoc Analysis of a Phase 3 Trial (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Alopecia • Immunology

JAK inhibitors for the off-label treatment of two stevens-johnson syndrome cases: tofacitinib vs. ivarmacitinib (EADV 2026) - No abstract available

Clinical • Steven-Johnson Syndrome

Safety Profiles of Ivarmacitinib versus Tofacitinib in Vitiligo Treatment: A Retrospective Comparative Analysis (EADV 2026) - No abstract available

Retrospective data • Dermatology • Immunology • Vitiligo

A retrospective observational study of oral ivarmacitinib and narrow-band ultraviolet-B in refractory progressive vitiligo (EADV 2026) - No abstract available

Observational data • Retrospective data • Dermatology • Immunology • Vitiligo

Efficacy of Ivarmacitinib in Vitiligo Treatment: A Retrospective Analysis of 7 Cases (EADV 2026) - No abstract available

Retrospective data • Dermatology • Immunology • Vitiligo

Twenty-four-week clinical outcomes and safety of oral ivarmacitinib in adults with stable non-segmental vitiligo: a real-world retrospective case series (EADV 2026) - No abstract available

Clinical data • Real-world • Real-world evidence • Retrospective data • Dermatology • Immunology • Vitiligo

OX40/OX40L Clinical Response Lag: A Systematic Review And Pharmacodynamic Analysis Of Amiltelimab, Rocatinlimab, And Ivarmacitinib. Proposing A New "Delayed Onset" Classification System For T-Cell Rebalancing Therapies In Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • PK/PD data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • TNFSF4

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis (clinicaltrials.gov) - P3 | N=418 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Enrolling by invitation ➔ Active, not recruiting | Trial completion date: Nov 2024 ➔ Dec 2026 | Trial primary completion date: Nov 2024 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Jiangsu Hengrui Medicine Co., Ltd...recently received a notification from the National Medical Products Administration...approving a fifth indication for ivarmacitinib sulfate Tablets (SHR0302 Tablets), a Class 1 innovative drug independently developed by the Company. (HKEXnews) - "Acceptance Number: CXHS2500141...Approved Indication: This product is indicated for adult patients with active non-radiographic axial spondyloarthritis who have had an inadequate response or intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) and exhibit objective signs of inflammation (manifested as elevated C-reactive protein [CRP] and/or abnormal magnetic resonance imaging [MRI] findings)....The approval for this new indication is based on a multicenter, randomized, double-blind, placebo-controlled pivotal Phase III study (SHR0302-305)."

China approval • Immunology • Spondylarthritis